BMY vs MCK: fair value comparison
Bristol-Myers Squibb Company and McKesson Corporation · Updated 2026-10-19
BMY currently screens as overvalued while MCK screens as fairly valued. Within Healthcare, MCK currently sits closer to the top of our ranking by discount to fair value. BMY carries the stronger quality grade.
| BMY | MCK | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $59.12 | $938.84 |
| 12-month range | $42.60–$68.09 | $725.17–$1,004.84 |
| Rank by discount to fair value | #72 of 108 Healthcare | #68 of 108 Healthcare |
| Quality grade | B | F |
| Leverage | High | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Overbought |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · MCK fair value analysis